Dequalinium

Dequalinium

SCHEMBL149457

Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 13/20 1.00
MEN1 O00255 4/20 1.00
GMNN O75496 4/20 1.00
LMNA P02545 4/20 1.00
POLB P06746 4/20 1.00
MAPT P10636 4/20 1.00
APEX1 P27695 4/20 1.00
RECQL P46063 4/20 1.00
BLM P54132 4/20 1.00
PMP22 Q01453 4/20 1.00
KMT2A Q03164 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
NPSR1 Q6W5P4 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
ALDH1A1 P00352 3/20 1.00
TP53 P04637 3/20 1.00
CYP3A4 P08684 3/20 1.00
HSD17B10 Q99714 3/20 1.00
CYP2D6 P10635 2/20 1.00
ALOX15 P16050 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299633 1.00 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL6305111 1.00 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL29577841 1.00 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL6298118 1.00 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL29557297 1.00 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL2335922 0.98 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL2544854 0.98 MEN1 (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL1008339 0.98 PRKCA (0.97) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL29613054 0.98 MEN1 (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL34043 0.98 MEN1 (1.00) PRKCAMEN1GMNNLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250352653-A1 NEURON TARGETED 2-DEOXYGLUCOSE DENDRIMER FOR IMAGING AND TREATMENT OF NEUROLOGICAL DISEASES UNIV WASHINGTON STATE (US) 2025-11-20 US claimed
US-20250271426-A1 REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS FIRMENICH INCORPORATED (US) 2025-08-28 US claimed
WO-2025137193-A1 BFL-1 INHIBITORS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-06-26 WO claimed
US-20250177373-A1 COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION THE CHILDEREN'S MEDICAL CENTER CORPORATION (US) 2025-06-05 US claimed
US-20250163388-A1 METHODS FOR DERIVATION AND PROPAGATION OF AVIAN PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2025-05-22 US claimed
US-20250144078-A1 THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF SYMERES NETHERLANDS B.V. (NL) 2025-05-08 US claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
WO-2025058566-A1 ORALLY-DELIVERED PLATINUM PRO-DRUG AGAINST CISPLATIN-RESISTANT OVARIAN CANCER NATIONAL UNIVERSITY OF SINGAPORE (SG) 2025-03-20 WO claimed
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity WASHINGTON UNIVERSITY (US) 2025-03-11 US claimed
EP-4493928-A1 REDUCTION OF BITTER TASTE OF ACTIVE PHARMACEUTICAL INGREDIENTS AND RELATED ASSAYS AND SCREENING METHODS Firmenich Incorporated (US) 2025-01-22 EP claimed
WO-1999013096-A1 MATERIALS AND METHODS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES UNIVERSITY OF FLORIDA (US) 1999-03-18 WO claimed
EP-0783292-A1 INHIBITION OF HAIR GROWTH HANDELMAN, Joseph H. (US) 1997-07-16 EP claimed
US-5554608-A INHIBITOR OF PROTEIN KINASE C GILLETTE COMPANY, THE, A DELAWARE CORPORATION 1996-09-10 US claimed
WO-1996009806-A2 INHIBITION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1996-04-04 WO claimed
EP-0617611-B1 ORAL OSMOTIC DEVICE ALZA CORP (US) 1996-01-31 EP claimed
EP-0399479-B1 CHEWING GUM FOR THE DISINFECTION OF THE MOUTH AND THE THROAT AND PROCESS FOR ITS PREPARATION Gergely, Gerhard, Dr. (AT) 1993-08-11 EP claimed
US-4946849-A Method for the treatment of malaria FLOW INCORPORATED (US) 1990-08-07 US claimed
EP-0148242-A4 METHOD AND APPARATUS FOR TREATING AILMENTS. KRAUSER ROBERT S 1987-06-03 EP claimed
EP-0148242-A1 METHOD AND APPARATUS FOR TREATING AILMENTS. KRAUSER ROBERT S 1985-07-17 EP claimed
WO-1985000112-A1 METHOD AND APPARATUS FOR TREATING AILMENTS KRAUSER ROBERT S 1985-01-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity NADK, NAPRT, TIPARP PRKCA 2174/4885MEN1 3678/4885GMNN 2521/4885
US-20250177373-A1 COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION HAVCR2, CD4, MAVS PRKCA 1569/4885MEN1 3851/4885GMNN 1645/4885
US-20250144078-A1 THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF TYMS, TOP1, TOP2A PRKCA 2656/4885MEN1 2742/4885GMNN 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.